Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00317213|
Recruitment Status : Completed
First Posted : April 24, 2006
Last Update Posted : April 14, 2008
|Condition or disease||Intervention/treatment||Phase|
|Smoking||Drug: LIBERTAL- a phospholipid mixture||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||500 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase IIB Study of the Efficacy and Safety of LIBERTAL, A Phosphatidic-Acid-Enriched Phospholipid, on Smoking Cessation|
|Study Start Date :||February 2002|
|Estimated Study Completion Date :||July 2002|
- Quit Smoking Rates - QSR% as confirmed by CO measurement in exhaled air.
- Safety as expressed by adverse-event reporting, clinical, hematological and biochemical parameters.
- Immunomodulatory potential of Libertal, as expressed by cytokine measurements in frozen cultured PBMC supernatants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00317213
|Arazi Clinic and Modus Clinic|
|Tel-Aviv and Rehovot, Israel|
|Principal Investigator:||Zeev T. Handzel, M.D.||Kaplan Medical Center|
|Study Director:||Avner Shenfeld, Ph.D,||Modus Biological Membranes|